Exelixis Announces U.S. FDA Accepts Supplemental New Drug Application for CABOMETYX (cabozantinib) in Previously Treated Advanced Hepatocellular Carcinoma

Understanding the true impact of living with FOP

Ipsen Announces Decision to Permanently Discontinue Distribution of NutropinAq® (somatropin) cartridges

Applications now open for the 2023 Golden Ticket Competition

Offering support to those impacted in Turkey & Syria

Ipsen delivers FY and Q4 2022 results – A word from CEO David Loew